Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

INTRODUCTION: The GLOBAL LEADERS is an open-label, pragmatic and superiority randomised controlled trial designed to challenge the current treatment paradigm of dual antiplatelet therapy (DAPT) for 12 months followed by aspirin monotherapy among patients undergoing percutaneous coronary intervention...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonardi, Sergio, Franzone, Anna, Piccolo, Raffaele, McFadden, Eugene, Vranckx, Pascal, Serruys, Patrick, Benit, Edouard, Liebetrau, Christoph, Janssens, Luc, Ferrario, Maurizio, Zurakowski, Aleksander, van Geuns, Robert-Jan, Dominici, Marcello, Huber, Kurt, Slagboom, Ton, Buszman, Paweł, Bolognese, Leonardo, Tumscitz, Carlo, Bryniarski, Krzysztof, Aminian, Adel, Vrolix, Mathias, Petrov, Ivo, Garg, Scot, Naber, Christoph, Prokopczuk, Janusz, Hamm, Christian, Steg, Gabriel, Heg, Dik, Juni, Peter, Windecker, Stephan, Valgimigli, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429932/
https://www.ncbi.nlm.nih.gov/pubmed/30852547
http://dx.doi.org/10.1136/bmjopen-2018-026053

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429932/
https://www.ncbi.nlm.nih.gov/pubmed/30852547
http://dx.doi.org/10.1136/bmjopen-2018-026053

Ejemplares similares